Investment Portfolio

BioGenerator Ventures is an early-stage investor in St. Louis-based life science companies. As of 2025, we have invested in over 130 companies across the human health and agriculture technology sectors. We are often the first professional capital into portfolio companies, and we actively syndicate deals with capital sources across the globe.

Filter

Pairidex logo

Pairidex

Detecting gene fusions with a patented ddPCR approach.

Status: Active
First Investment Year: 2024

Panome Bio logo

Panome Bio

Next-generation metabolomics® and proteomics with integrated multi-omic data analysis.

Status: Active
First Investment Year: 2022

Agragene logo

Agragene

Using gene editing to develop a novel sterile insect technology approach for pest control.

Status: Active
First Investment Year: 2022

Solis logo

Solis

Accelerates agricultural innovation through specialized research services like plant transformation, gene editing, and consulting.

Status: Active
First Investment Year: 2021

Geneoscopy logo

Geneoscopy

RNA detection platform to screen for colorectal cancer and other GI diseases.

Status: Active
First Investment Year: 2021

SweetSpot logo

SweetSpot

Virtual care and remote patient monitoring platform for diabetes care providers.

Status: Active
First Investment Year: 2020

Omniose logo

Omniose

Expanding the range of bioconjugate vaccines to fight more bacterial threats.

Status: Active
First Investment Year: 2019

Wugen logo

Wugen

Developing off-the-shelf cellular therapies for cancer.

Status: Active
First Investment Year: 2018

Impetus Agriculture logo

Impetus Agriculture

Enhancing the performance of Bt biopesticides for safer, more effective, and sustainable insect control solutions.

Status: Active
First Investment Year: 2018

Plastomics logo

Plastomics

Harnessing chloroplasts in plant cells to deliver traits that enhance crop yields, resistance, and efficiency.

Status: Active
First Investment Year: 2017

SentiAR logo

SentiAR

AR technology to provide physicians with a 360-degree view of the treatment they’re delivering.

Status: Active
First Investment Year: 2017

MediBeacon logo

MediBeacon

Developing fluorescent tracer agents and transdermal detection technology for physiological monitoring.

Status: Active
First Investment Year: 2012

Amplifi Vascular logo

Amplifi Vascular

Proprietary blood pump system to increase eligibility and improve outcomes for arteriovenous fistula surgery.

Status: Active
First Investment Year: 2025

Spearhead Bio logo

Spearhead Bio

Novel molecular approach for precise trait insertion in plant genomes.

Status: Active
First Investment Year: 2025

Prognosia logo

Prognosia

Using artificial intelligence to predict breast cancer risk and inform treatment paths.

Status: Active
First Investment Year: 2025

Equator Therapeutics logo

Equator Therapeutics

Small molecule therapeutics for the treatment of obesity.

Status: Active
First Investment Year: 2024

Aurenar logo

Aurenar

Disposable, transcutaneous auricular vagus nerve stimulator to reduce complications in the ICU.

Status: Active
First Investment Year: 2024

Pyrone Systems  logo

Pyrone Systems

Utilizes a bio-molecular platform based on Triacetic Acid Lactone (TAL) to produce novel and safe pesticides.

Status: Active
First Investment Year: 2024

Lingrove logo

Lingrove

Designs and manufactures eco-friendly, high-performance materials made from plant-based fibers for architecture and automotive industries.

Status: Active
First Investment Year: 2024

Miller Biosciences logo

Miller Biosciences

Improving grip ability by blocking hyperhydrosis.

Status: Active
First Investment Year: 2023

Get Help logo

Get Help

Helping providers do their jobs more effectively and efficiently.

Status: Active
First Investment Year: 2023

Forward Defense logo

Forward Defense

Developing a novel vaccine against staphylococcus aureus.

Status: Active
First Investment Year: 2023

CapyBio logo

CapyBio

Developing computational tools to improve cell differentiation and iPSC engineering.

Status: Active
First Investment Year: 2023

CAELIVascular logo

CAELIVascular

Multi-modal thrombectomy device for the treatment of deep vein thrombosis.

Status: Active
First Investment Year: 2023

Axioforce logo

Axioforce

Developing small electromagnetic sensors for force sensing applications.

Status: Active
First Investment Year: 2023

Arch Grain Technologies  logo

Arch Grain Technologies

Empowering renewable energy through oil extraction to revitalize corn demand.

Status: Active
First Investment Year: 2023

Ferris Genomics logo

Ferris Genomics

Provides technologies and services for breeding genomics.

Status: Exit
First Investment Year: 2023

AgXelerators logo

AgXelerators

Provides formulation services to transform novel ingredients into stable and effective products for agriculture.

Status: Active
First Investment Year: 2023

Saluna logo

Saluna

Developing industrial hemp as a competitive grain crop alternative for oil, food, and feed.

Status: Active
First Investment Year: 2023

Norfolk logo

Norfolk

Bringing a portfolio of health-benefitting traits in fruits & vegetables, starting with the Purple Tomato™.

Status: Active
First Investment Year: 2023

Intent logo

Intent

Helps agribusinesses execute seamless field trials and data analysis for the trusted results needed to drive product success.

Status: Active
First Investment Year: 2023

bioio logo

bioio

Mechanism of action technologies (MOAT) platform for drug target identification and development.

Status: Active
First Investment Year: 2023

Spectrum Perception

Creating "sensible instruments"​ for use in scientific analyses.

Status: Active
First Investment Year: 2022

LiquidCell Dx logo

LiquidCell Dx

Immune checkpoint blockade therapy response prediction.

Status: Active
First Investment Year: 2022

Kinimmune logo

Kinimmune

Tissue retentive formulations for safer, more effective cancer immunotherapy treatments.

Status: Active
First Investment Year: 2022

RevivBio logo

RevivBio

Establishing a discovery platform for designing new proteins for a wide range of applications; the first product is a bio-fungicide.

Status: Active
First Investment Year: 2022

Agrela Ecosystems  logo

Agrela Ecosystems

Creates a customizable, crop-plot environmental sensor and phenotyping station for real-time measurements of environmental conditions.

Status: Active
First Investment Year: 2022

Peptyde Bio logo

Peptyde Bio

Discovering and designing novel anti-microbial peptides as alternatives to chemical fungicides.

Status: Exit
First Investment Year: 2022

Aferna logo

Aferna

Creating an innovative method for regulating gene expression to produce crops with improved traits.

Status: Active
First Investment Year: 2022

Syndeavor Therapeutics logo

Syndeavor Therapeutics

Developing a small molecule inhibitor of ACSS2 for the treatment of TNBC and NSCLC.

Status: Active
First Investment Year: 2021

Immune Functional Diagnostics (IFDx)

Sepsis patient prognostication and segmentation through immunophenotyping.

Status: Active
First Investment Year: 2021

InterShunt logo

InterShunt

Developing a transcatheter system to safely excise tissue and treat heart failure patients.

Status: Active
First Investment Year: 2021

Aptimmune Biologics logo

Aptimmune Biologics

Advancing vaccine technology to solve challenging swine diseases.

Status: Active
First Investment Year: 2021

Bond Biosciences logo

Bond Biosciences

Developing first-in-class non-absorbed oral therapeutics to prevent and treat iron-related diseases.

Status: Active
First Investment Year: 2021

RhoDx logo

RhoDx

Unleashing the power of liquid biopsy to detect and fight cancer.

Status: Active
First Investment Year: 2021

Wakyn Sleep Technologies logo

Wakyn Sleep Technologies

Enabling therapy access to undiagnosed sleep apnea patients with the first rapid, awake diagnostic.

Status: Active
First Investment Year: 2020

OpenCell Technologies logo

OpenCell Technologies

A novel system for delivery of cargo to difficult to transfect cell types.

Status: Active
First Investment Year: 2020

Cadex Genomics logo

Cadex Genomics

Developing a test to monitor disease progression in cancer patients via cfDNA

Status: Active
First Investment Year: 2020

Myonid logo

Myonid

Advancing therapeutic treatments for liver diseases and heart failure.

Status: Active
First Investment Year: 2020

CuriMeta logo

CuriMeta

Curating, enhancing, and transforming real-world, de-identified health data to help researchers solve clinical challenges.

Status: Exit
First Investment Year: 2020

Precision Virologics  logo

Precision Virologics

Developing advanced adenoviral vaccines.

Status: Active
First Investment Year: 2020

Lymbus Oncology logo

Lymbus Oncology

Developing anti-VEGFR-3 monoclonal antibodies for the treatment of cancer.

Status: Active
First Investment Year: 2020

Start Right Foods logo

Start Right Foods

Offering fast and convenient high-protein waffle sandwiches.

Status: Active
First Investment Year: 2019

Cadre Bioscience logo

Cadre Bioscience

Accelerating the development of multiple early-stage therapeutic assets.

Status: Active
First Investment Year: 2019

Aggio logo

Aggio

Provides cloud-based, digital solutions for companies in the agriculture & animal health industries.

Status: Active
First Investment Year: 2019

Kalocyte logo

Kalocyte

Developing a dried, bio-inspired artificial red blood cell to treat life-threatening blood loss.

Status: Active
First Investment Year: 2018

OxaluRx logo

OxaluRx

Developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease.

Status: Active
First Investment Year: 2018

Atomation logo

Atomation

Addresses key challenges related to equipment, machinery, and the environment using wireless IoT sensors.

Status: Active
First Investment Year: 2017

BlueStrata logo

BlueStrata

Cloud-based EHR for long-term post-acute care providers.

Status: Exit
First Investment Year: 2017

Medaware Solutions logo

Medaware Solutions

Empowering care teams, patients and family to overcome the inherent challenges of care coordination.

Status: Active
First Investment Year: 2016

Edison Agrosciences logo

Edison Agrosciences

Establishing a more sustainable and domestic source of natural rubber using sunflowers.

Status: Active
First Investment Year: 2016

Courier Therapeutics logo

Courier Therapeutics

Harnessing patient data and AI-driven technology to transform the discovery and development of life-changing medicines.

Status: Exit
First Investment Year: 2016

Canopy Biosciences logo

Canopy Biosciences

Providing access to cutting-edge spatial biology and multi-omic tools so researchers can drive scientific discovery.

Status: Exit
First Investment Year: 2016

Elira logo

Elira

Developing an external wearable device to aid in low calorie diet compliance.

Status: Active
First Investment Year: 2015

Katalyst logo

Katalyst

Surgical retina instrumentation.

Status: Exit
First Investment Year: 2015

CareSignal logo

CareSignal

Remote patient monitoring for value-based organizations.

Status: Exit
First Investment Year: 2015

Cofactor Genomics logo

Cofactor Genomics

Predictive diagnostics to match cancer patients to immunotherapy treatment.

Status: Active
First Investment Year: 2015

Accuronix Therapeutics logo

Accuronix Therapeutics

Utilizing a novel drug-targeting technology for cancer therapy.

Status: Active
First Investment Year: 2015

Unleash Immuno Oncolytics logo

Unleash Immuno Oncolytics

Developing virus immunotherapy products to treat cancer.

Status: Active
First Investment Year: 2015

Prostate Management Diagnostics logo

Prostate Management Diagnostics

Developing novel tests for prostate cancer.

Status: Active
First Investment Year: 2014

Daya CNS  logo

Daya CNS

Developing small molecule compounds for the treatment of CNS disorders including chronic pain and addiction.

Status: Active
First Investment Year: 2014

SynerZ logo

SynerZ

Medical devices for obesity and type 2 diabetes.

Status: Exit
First Investment Year: 2014

Immunophotonics logo

Immunophotonics

Pioneering the field of interventional immuno-oncology through novel treatments for solid-tumor cancers.

Status: Active
First Investment Year: 2014

Traxxsson logo

Traxxsson

Developing serum tests that will distinguish aggressive from indolent cancers.

Status: Active
First Investment Year: 2013

Kogent logo

Kogent

Specializing in electrosurgery, surgical site illumination and microsurgical instrumentation.

Status: Exit
First Investment Year: 2013

Bacterioscan logo

Bacterioscan

Detecting UTIs directly from urine samples.

Status: Active
First Investment Year: 2013

Benson Hill logo

Benson Hill

Unlocking nature’s genetic diversity in soy quality traits.

Status: Exit
First Investment Year: 2013

Graematter logo

Graematter

Enabling easier access to regulatory information with a novel regulatory intelligence system.

Status: Active
First Investment Year: 2012

Ionic Transport logo

Ionic Transport

Establishing and performing novel safety pharmacology assays to evaluate the safety of therapeutics on ion channel function in heart tissue.

Status: Exit
First Investment Year: 2011

Rnaissance logo

Rnaissance

Specializes in RNAi-based biopesticides for sustainable pest management.

Status: Active
First Investment Year: 2011

Kypha logo

Kypha

Delivers real-time information on highly-labile cytokines to bring faster, more precise clinical decisions within reach.

Status: Active
First Investment Year: 2011

ArrayBridge logo

ArrayBridge

Addressing two areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis.

Status: Exit
First Investment Year: 2011

Apertus Pharmaceuticals logo

Apertus Pharmaceuticals

Manufacturing Active Pharmaceutical Intermediates for Class II-V controlled substances.

Status: Exit
First Investment Year: 2011

Mobius Therapeutics logo

Mobius Therapeutics

Ophthalmic perioperative pharmaceuticals.

Status: Exit
First Investment Year: 2011

Euclises logo

Euclises

Advancing the next generation of oral drugs that disrupt the tumor microenvironment and kill cancer cells.

Status: Active
First Investment Year: 2011

SARmont logo

SARmont

Providing unique medicinal chemistry services to advance drug discovery.

Status: Exit
First Investment Year: 2010

Euphrates Vascular logo

Euphrates Vascular

Treating blood clots in stroke patients with magnetic nanoparticles.

Status: Active
First Investment Year: 2010

Confluence Discovery logo

Confluence Discovery

Providing biochemistry, biomarker, target validation and other services to pharma and academic clients.

Status: Exit
First Investment Year: 2010

Electrochaea logo

Electrochaea

Using microbes to convert carbon dioxide to renewable methane, which replaces fossil fuels.

Status: Active
First Investment Year: 2010

Galera Therapeutics logo

Galera Therapeutics

Developing novel therapies that have the potential to improve the anti-cancer efficacy of treatments for breast cancer.

Status: Exit
First Investment Year: 2010

Neurolutions logo

Neurolutions

Improving motor recovery after a stroke with brain-computer interfaces.

Status: Active
First Investment Year: 2008

APT logo

APT

Transforming human apyrase into life-saving medicine.

Status: Exit
First Investment Year: 2006

Photo of Joseph Monahan

Joseph Monahan

Co-Founder and CSO, Confluence (NASDAQ:ACRS)

“BioGenerator was deeply committed to working with the founders to build a successful company.  Without the ongoing support of BioGenerator, the Confluence story would never have happened.”

Photo of Matthew B. Crisp

Matthew B. Crisp

Co-Founder and CEO, Benson Hill (NYSE:BHIL)

“BioGenerator played a critical role in leading our initial financing - putting together the due diligence and orchestrating additional investors. Their commitment to supporting Benson Hill in multiple ways beyond their share of invested capital is part of the reason we are excited to call St. Louis home.”

Photo of Scott Horner

Scott Horner

Managing Director, Middleland Capital

“BioGenerator’s model has helped grow companies like Benson Hill into quality, highly-attractive investments for venture investors.”

Photo of Steve Hanley

Steve Hanley

Co-Founder and CEO, MediBeacon

“The network BioGenerator has is really invaluable and their active support from pre-company licensing through our Series A round was critical in getting the company to where it is today.”

Photo of Sach Chitnis

Sach Chitnis

General Partner, Jump Capital

“BioGenerator is a significant value-add investor, while also being a great source of life science deal flow. The quality of the investment opportunity combined with the professionalism they brought to due diligence and the deal process allowed us to move very quickly.”

Photo of Jennifer Avari Silva

Jennifer Avari Silva

Co-Founder and CMO, SentiAR

“BioGenerator has been instrumental in launching our company—from learning how to be successful academic founders to the details of starting and financing SentiAR, our spin out from Washington University. They have made crucial introductions to industry leaders at appropriate times and invested in our company. We could not have embarked down this path without all the support from the BioGenerator team!”

Photo of Dan Watkins

Dan Watkins

Managing Director, Mercury Fund

“The St. Louis startup community is flourishing. We’ve discovered and invested in several of our most promising companies there. I continue to be impressed by the BioGenerator model and the quality of its portfolio.”